Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Cariprazine
Drug: Aripiprazole

First Posted Date: 2010-04-15

Last Posted Date: 2018-10-29

Lead Sponsor: Forest Laboratories

Target Recruit Count: 617

Registration Number: NCT01104766

Locations: 🇺🇸
Synergy Clinical Research of Escondido, Escondido, California, United States
🇺🇸
Excell Research, Inc, Oceanside, California, United States
🇺🇸
Colorado Clinical Trials, Inc., Littleton, Colorado, United States

and more 55 locations

Aripiprazole and Prolactin Study

Phase 4

Completed

Conditions: Hyperprolactinemia

First Posted Date: 2010-03-11

Last Posted Date: 2015-05-28

Lead Sponsor: University of Oxford

Target Recruit Count: 15

Registration Number: NCT01085383

Locations: 🇬🇧
University Dept. of Psychiatry, Oxford, Oxfordshire, United Kingdom

ARIpiprazole in Anorexia NErvosa

Phase 3

Conditions: Anorexia Nervosa

Interventions: Drug: aripiprazole
Drug: placebo

First Posted Date: 2010-03-09

Last Posted Date: 2013-02-22

Lead Sponsor: Juan A. Arnaiz

Target Recruit Count: 60

Registration Number: NCT01082848

Locations: 🇪🇸
Hospital Clinic, Barcelona, Catalonia, Spain

Standard Comprehensive Intervention to Treat First-episode Schizophrenia

Not Applicable

Conditions: Schizophrenia

Interventions: Drug: risperidone
Drug: Aripiprazole
Drug: olanzapine

First Posted Date: 2010-01-27

Last Posted Date: 2010-01-27

Lead Sponsor: Peking University

Target Recruit Count: 600

Registration Number: NCT01057849

Locations: 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China
🇨🇳
Zhongnan University Xiangya Second Hospital, Changsha, Hunan, China
🇨🇳
Beijing Huilongguan Hospital, Beijing, Beijing, China

and more 3 locations

Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

Completed

Conditions: Anorexia Nervosa
Depression
ADHD

Interventions: Drug: Olanzapine
Drug: Atomoxetine
Drug: Duloxetine
Drug: Aripiprazole

First Posted Date: 2010-01-27

Last Posted Date: 2019-03-06

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 200

Registration Number: NCT01057329

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole
Drug: Olanzapine
Drug: Haloperidol

First Posted Date: 2010-01-20

Last Posted Date: 2014-04-10

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 300

Registration Number: NCT01052389

Locations: 🇮🇹
Department of Mental Health, Genoa, Liguria, Italy

FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders

Phase 4

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Aripiprazole

First Posted Date: 2009-12-09

Last Posted Date: 2014-03-11

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 13

Registration Number: NCT01028820

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Efficacy and Safety of Aripiprazole in First Episode Psychosis

Phase 4

Completed

Conditions: First Episode Psychosis

Interventions: Drug: Aripiprazole

First Posted Date: 2009-12-04

Last Posted Date: 2012-02-13

Lead Sponsor: Chonbuk National University Hospital

Target Recruit Count: 55

Registration Number: NCT01026584

Locations: 🇰🇷
Department of Psychiatry, Kangwon National University College of Medicine, Chunchon, Korea, Republic of
🇰🇷
Department of Psychiatry, Inje University College of Medicine, Ilsan Paik Hospital, Goyang, Korea, Republic of
🇰🇷
Department of Psychiatry, Kyungpook national University School of Medicine, Daegu, Korea, Republic of

and more 10 locations